Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Davydovskaya

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 18, 2015
[Criteria of ineffectiveness of treatment with first-line therapy: how to use MRI results in decision making?]N V Khachanova, M V Davydovskaya
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 1, 2017
[The three-year follow-up study of retinal changes in patients with multiple sclerosis]M A Zhostkova, M V Davydovskaya, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 5, 2021
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis]N A Avxentyev, M V Davydovskaya, Y V Makarova, et al.
Neuroscience and Behavioral Physiology|May 12, 2009
Efficacy and safety of prolonged immunomodulatory treatment with interferon betaT L Demina, N V Khachanova, M V Davydovskaya, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 1, 2015
[Autoimmune encephalitis]M V Davydovskaya, A N Boyko, I A Beliaeva, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 15, 2020
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis]M V Zhuravleva, M V Davydovskaya, E V Luchinina, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 24, 2018
[The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy]E V Popova, K V Novikova, N V Khachanova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 18, 2015
[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center]O G Borets, M V Davydovskaya, T L Demina, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 24, 2020
[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|March 3, 2017
[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis]V M Alifirova, A N Boiko, Ya V Vlasov, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 18, 2015
[Criteria of ineffectiveness of treatment with first-line therapy: how to use MRI results in decision making?]N V Khachanova, M V Davydovskaya
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 1, 2017
[The three-year follow-up study of retinal changes in patients with multiple sclerosis]M A Zhostkova, M V Davydovskaya, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 5, 2021
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis]N A Avxentyev, M V Davydovskaya, Y V Makarova, et al.
Neuroscience and Behavioral Physiology|May 12, 2009
Efficacy and safety of prolonged immunomodulatory treatment with interferon betaT L Demina, N V Khachanova, M V Davydovskaya, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 1, 2015
[Autoimmune encephalitis]M V Davydovskaya, A N Boyko, I A Beliaeva, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 15, 2020
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis]M V Zhuravleva, M V Davydovskaya, E V Luchinina, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 24, 2018
[The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy]E V Popova, K V Novikova, N V Khachanova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 18, 2015
[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center]O G Borets, M V Davydovskaya, T L Demina, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 24, 2020
[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|March 3, 2017
[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis]V M Alifirova, A N Boiko, Ya V Vlasov, et al.
Pageof 2